Outcome of combination antiviral therapy in hepatitis C virus infected patients with sickle cell disease.
Alavian
Seyed-Moayed
SM
Tabatabaei
Seyed-Vahid
SV
Ayyub
Mohammad
M
D000755:Anemia, Sickle Cell / Q000150:complications*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin